March 10 (Reuters) - Tonix Pharmaceuticals Holding Corp TNXP.O:
TONIX PHARMACEUTICALS ANNOUNCES GRANT BY MEDICAL CBRN DEFENSE CONSORTIUM (MCDC) FOR DEVELOPMENT OF TNX-801, THE COMPANY’S SINGLE-DOSE MPOX AND SMALLPOX VACCINE CANDIDATE
TONIX PHARMACEUTICALS: TOLERABILITY OF TNX‐801 VACCINATION IN IMMUNE-COMPROMISED ANIMAL MODELS SUPPORTS CLINICAL DEVELOPMENT
Source text: nGNX5xStzg
Further company coverage: TNXP.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.